Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 55.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 172,474 shares of the biotechnology company’s stock after selling 215,230 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Rocket Pharmaceuticals were worth $5,169,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RCKT. JPMorgan Chase & Co. grew its stake in Rocket Pharmaceuticals by 22.6% during the 1st quarter. JPMorgan Chase & Co. now owns 837,915 shares of the biotechnology company’s stock valued at $13,289,000 after purchasing an additional 154,739 shares in the last quarter. HighTower Advisors LLC grew its stake in Rocket Pharmaceuticals by 30.3% during the 1st quarter. HighTower Advisors LLC now owns 21,000 shares of the biotechnology company’s stock valued at $336,000 after purchasing an additional 4,879 shares in the last quarter. MetLife Investment Management LLC grew its stake in Rocket Pharmaceuticals by 56.6% during the 1st quarter. MetLife Investment Management LLC now owns 22,975 shares of the biotechnology company’s stock valued at $364,000 after purchasing an additional 8,301 shares in the last quarter. Rhumbline Advisers grew its stake in Rocket Pharmaceuticals by 3.7% during the 1st quarter. Rhumbline Advisers now owns 44,652 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 1,575 shares in the last quarter. Finally, Synovus Financial Corp grew its position in shares of Rocket Pharmaceuticals by 29.4% in the 1st quarter. Synovus Financial Corp now owns 82,236 shares of the biotechnology company’s stock worth $1,306,000 after acquiring an additional 18,663 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 3,576 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $29.84, for a total transaction of $106,707.84. Following the sale, the general counsel now owns 6,136 shares of the company’s stock, valued at approximately $183,098.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 3,576 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 16th. The stock was sold at an average price of $29.84, for a total transaction of $106,707.84. Following the sale, the general counsel now owns 6,136 shares of the company’s stock, valued at approximately $183,098.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Gaurav Shah sold 20,272 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $29.84, for a total value of $604,916.48. Following the sale, the chief executive officer now directly owns 554,762 shares in the company, valued at approximately $16,554,098.08. The disclosure for this sale can be found here. Insiders have sold 334,740 shares of company stock valued at $9,529,027 in the last quarter. Corporate insiders own 31.10% of the company’s stock.

Rocket Pharmaceuticals Trading Down 0.7 %

NASDAQ:RCKT opened at $24.01 on Tuesday. Rocket Pharmaceuticals, Inc. has a 12-month low of $14.89 and a 12-month high of $32.53. The firm has a market capitalization of $2.17 billion, a P/E ratio of -8.17 and a beta of 1.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.80 and a quick ratio of 7.80. The business has a 50 day simple moving average of $27.65 and a 200 day simple moving average of $25.26.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.14. During the same period last year, the business posted ($0.92) EPS. Equities research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Wall Street Analyst Weigh In

RCKT has been the subject of several research reports. Lifesci Capital reiterated an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, December 26th. Needham & Company LLC reiterated a “buy” rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 10th. The Goldman Sachs Group initiated coverage on Rocket Pharmaceuticals in a research report on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 target price for the company. UBS Group decreased their target price on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. decreased their target price on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $52.13.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.